Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial
Surgery - Renal Transplantation, Catholic University, Rome, Italy
Meeting: 2013 American Transplant Congress
Abstract number: C1339
Purpose. The aim of this prospective, exploratory, single center study in kidney transplantation was to compare two immunosuppressive induction regimens: thymoglobulin plus basiliximab (THY) versus basiliximab (BAX).
Methods. Sixty deceased donor kidney transplant recipients were prospectively assigned to THY (30 pts) or BAX (30 pts) and followed up for 1 year. As induction therapy patients assigned to THY received a combination of thymoglobulin (50 mg/day iv from day 0 to day 3, total dose 200 mg) and basiliximab (20 mg iv on day 0 and day 4), while recipients allocated to BAX received only basiliximab (20 mg iv on day 0 and day 4). As maintenance all patients received tacrolimus, MMF and steroids. Steroids in the THY group were selectively withdrawn after 6 months in patients with no previous transplantation, no acute rejection episodes, serum creatinine < 2 mg/dL and proteinuria < 300 mg/24 h.
Results. Demographic characteristics of patients were similar in the two groups. Efficacy and safety parameters after 1 year of follow up are summarized in the table.
| THY | BAX | p | |
| Patients (#) | 30 | 30 | |
| Patient survival (%) | 100 | 100 | ns |
| Graft survival (%) | 100 | 97 | ns |
| BPAR (%) | 10 | 14 | ns |
| Serum creatinine (mg/dL) | 1.5±0.4 | 1.4±0.4 | ns |
| Creatinine clearance (mL/min) | 55±20 | 60±19 | ns |
| Proteinuria (g/24h) | 0.1±0.2 | 0.2±0.4 | ns |
| Hemoglobin (g/dL) | 12.7±1.4 | 13.6±1.7 | ns |
| WBC count (cellx10^3/mL) | 6.7±2.5 | 6.5±1.3 | ns |
| Platelet count (cellx10^3/mL) | 274±153 | 197±45 | <0.05 |
| Total cholesterol (mg/dL) | 209±53 | 210±38 | ns |
| Triglycerides level (mg/dL) | 185±22 | 168±125 | ns |
| Systolic blood pressure (mmHg) | 125±13 | 129±13 | ns |
| Diastolic blood pressure (mmHg) | 73±7 | 78±10 | <0.05 |
| Dislipidemia on treatment (%) | 29 | 21 | ns |
| NODAT (%) | 3 | 7 | ns |
| CMV disease (%) | 0 | 0 | ns |
| PVAN (%) | 0 | 0 | ns |
| Tacrolimus C0 (ng/mL) | 6.5±1.6 | 8.3±3.3 | <0.05 |
| Tacrolimus C2 (ng/mL) | 11.3±4.9 | 14.4±5.6 | <0.05 |
| MMF daily dose (mg) | 989±53 | 947±158 | ns |
| Steroids daily dose (mg) | 2.4±2.1 To cite this abstract in AMA style: Favi E, Spagnoletti G, Silvestrini N, Salerno M, Pedroso J, Romagnoli J, Citterio F. Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/thymoglobulin-plus-basiliximab-vs-basiliximab-as-induction-therapy-in-deceased-donor-kidney-transplant-recipients-treated-with-tacrolimus-and-mycophenolate-mofetil-1-year-results-of-a-prospective-cli/. Accessed April 4, 2020.« Back to 2013 American Transplant Congress |